CN108096313A - A kind of pharmaceutical composition for treating virile diesae and its preparation method and application - Google Patents
A kind of pharmaceutical composition for treating virile diesae and its preparation method and application Download PDFInfo
- Publication number
- CN108096313A CN108096313A CN201810118690.9A CN201810118690A CN108096313A CN 108096313 A CN108096313 A CN 108096313A CN 201810118690 A CN201810118690 A CN 201810118690A CN 108096313 A CN108096313 A CN 108096313A
- Authority
- CN
- China
- Prior art keywords
- hot water
- water extract
- pharmaceutical composition
- parts
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/39—Convolvulaceae (Morning-glory family), e.g. bindweed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/43—Cuscutaceae (Dodder family), e.g. Cuscuta epithymum or greater dodder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention relates to a kind of pharmaceutical composition for treating virile diesae, described pharmaceutical composition according to the mass fraction, including following component：10 30 parts of agate card hot water extract, 10 30 parts of Tongkat Ali hot water extract, 15 40 parts of Semen Cuscutae hot water extract, 15 40 parts of Butea superba hot water extract, 5 20 parts of American Ginseng powder.The pharmaceutical composition of the present invention can significantly reduce prostate wet weight in prostatic hyperplasia model rat, the volume density of prostate index and prostate gland and to significantly reduce T, EGF in the homogenate of rat model prostate horizontal；And find that the medicine composite for curing hyperplasia of prostate in the present invention has good effect through unofficial clinical research.The pharmaceutical composition of the present invention can enhance immune function, rapid recovery fatigue, enhancing Male vitality, enhancement fecundity and treatment male sexual disfunction, can be prepared into relevant healthcare product or drug.
Description
Technical field
The present invention relates to the drug fields for the treatment of virile diesae, and in particular to a kind of pharmaceutical composition for treating virile diesae
And its preparation method and application.
Background technology
Hyperplasia of prostate (BPH) is one of middle-aging male common disease, is fallen ill with population in the world astogeny increased.
The incidence of hyperplasia of prostate is incremented by with the age, but not necessarily there are clinical symptoms in while having preneoplastic lesions.Cities and towns incidence is higher than township
Village, and racial difference also influences hyperplasia degree.Hyperplasia of prostate is called " the four big killers " of elderly men, many old men
Property all suffered from such disease, it is physically and mentally healthy that hyperplasia of prostate seriously endangers elderly men.The generation of hyperplasia of prostate must have
Two essential conditions of growth and functional testis at standby age.But the specific mechanism that hyperplasia of prostate occurs is still not clear, can
Caused by being the multiplication of epithelium and interstitial cell and the balance destruction of Apoptosis.In addition, also have some correlative factors, than
As said, androgen and its with the interaction of estrogen, the prostate interstitial-interaction of glandular epithelium, growth factor, inflammation
Disease cell, neurotransmitter and inherent cause etc..The incidence of hyperplasia of prostate is increased with the growth at age in histology, most
It is just usually happened at after 40 years old, to when being more than 50%, 80 years old at 60 years old up to 83%.It is similar with histological appearance, with
The symptoms such as the growth at age, dysuria are consequently increased.During the male of about 50% histodiagnosis hyperplasia of prostate has
Spend severe lower urinary tract symptom.
Symptom that forefront hyperplasia disease occurs earliest and most important be enuresis nocturna number increase, urinate it is slow, powerless, and
And this symptom is in the trend slowly aggravated.Patient occurs being earliest slightly to block, for example urinates line carefully without smooth, however at this time
It does not arouse attention mostly.With progression of the disease, frequent micturition is occurred as soon as, enuresis nocturna number increases, urine is laborious, urine is out of control, until the retention of urine (row
Do not go out urine to come).The complication such as urinary tract infections, vesical calculus, inguinal hernia, hemorrhoid may be also present with.Some patientss can go out
The performance of existing overactive bladder, this is a kind of syndrome characterized by symptoms of urgency, is often accompanied by frequent micturition and nocturia,
Can even occur overflow incontinence when serious with or without urge incontinence.
At present, hyperplasia of prostate is treated in the market mostly using steroids or antihormones class drug, alpha adrenergic receptor retardance
Agent, 5 α receptors reductase inhibitors, cholesterol inhibitor, galenical, Chinese medicine treatment etc..Certainly, prostatic hyperplasia agents are controlled
The symptom that should be directed to patient, the progress factors such as risk and therapeutic response are treated, are examined in drug dose, the course for the treatment of, drug combination etc.
Consider individualized treatment.In terms of the course for the treatment of, for symptom is apparent, the dangerous larger patient of clinical progress uses α receptor blocker+5
The therapeutic alliance of alpha-reductase inhibitors is typically all long-term administration.Drug therapy hyperplasia of prostate shortcoming includes：Side effect
Greatly, dependence is also easy to produce, larger harm is generated to cardio-cerebrovascular, immune system after long term usage.And due to western medicine for
The basic reason and pathogenesis of hyperplasia of prostate are not yet fully apparent from, thus Western medicine is with improvement and relief of symptoms in the treatment
Based on rather than radical cure hyperplasia of prostate.
The content of the invention
In view of this, in order to solve problem of the prior art, the present invention provides one kind can enhance immune function, quick
Fatigue-relieving, enhancing Male vitality promote fecundity and treat the pharmaceutical composition of male sexual disfunction.
In order to achieve the above object, the present invention adopts the following technical scheme that：
A kind of pharmaceutical composition for treating virile diesae, described pharmaceutical composition according to the mass fraction, including following component：
10-30 parts of agate card hot water extract, 10-30 parts of Tongkat Ali hot water extract, 15-40 parts of Semen Cuscutae hot water extract, gorgeous purple
15-40 parts of riveting hot water extract, 5-20 parts of American Ginseng powder.
Preferably, described pharmaceutical composition according to the mass fraction, including following component：Agate card hot water extract 18.75
Part, 18.75 parts of Tongkat Ali hot water extract, 25 parts of Semen Cuscutae hot water extract, 25 parts of Butea superba hot water extract, American Ginseng
12.5 parts of powder.
Preferably, the dosage form of described pharmaceutical composition is effervescent tablet, buccal tablet, granule, capsule or oral liquid.
The present invention also provides a kind of preparation methods for the pharmaceutical composition for treating virile diesae, which is characterized in that described
Pharmaceutical composition according to the mass fraction, including following component：10-30 parts of agate card hot water extract, Tongkat Ali hot water extract
10-30 parts, 15-40 parts of Semen Cuscutae hot water extract, 15-40 parts of Butea superba hot water extract, 5-20 parts of American Ginseng powder；
The preparation method of described pharmaceutical composition includes following preparation process：
The preparation process of the agate card hot water extract is：Dry maca powder is broken, and add boiling boiling extraction, filter medicine
Slag, get Ma Ka hot water extract's powder after the liquid spray being obtained by filtration is dried；
The preparation process of the Butea superba hot water extract is：Dry Butea superba is crushed, and adds boiling boiling extraction, mistake
The dregs of a decoction are filtered, Butea superba hot water extract's powder is obtained after the liquid spray being obtained by filtration is dried；
The preparation process of the Tongkat Ali hot water extract is：Dry Tongkat Ali is crushed, adds boiling boiling extraction,
The dregs of a decoction are filtered, Tongkat Ali hot water extract's powder is obtained after the liquid spray being obtained by filtration is dried；
The preparation process of the Semen Cuscutae hot water extract is：Dry Semen Cuscutae is crushed, and adds boiling boiling extraction, mistake
The dregs of a decoction are filtered, Semen Cuscutae hot water extract's powder is obtained after the liquid spray being obtained by filtration is dried；
The preparation process of the American Ginseng powder is：Dry American Ginseng is taken to crush, sieves, obtains American Ginseng powder.
Preferably, the preparation process of the agate card hot water extract is specially：Dry maca powder is broken, and add boiling boiling
The mass ratio of extraction 2h, Ma Ka and water is 1:10, the dregs of a decoction are filtered, obtaining agate card hot water after the liquid spray being obtained by filtration is dried carries
Take object powder.
Preferably, the preparation process of the Butea superba hot water extract is specially：Dry Butea superba is crushed, and adds water
It boils and extracts 1h, the mass ratio of Butea superba and water is 1:10, the dregs of a decoction are filtered, gorgeous purple is obtained after the liquid spray being obtained by filtration is dried
Riveting hot water extract's powder.
Preferably, the preparation process of the Tongkat Ali hot water extract is specially：Take dry Tongkat Ali tree root powder
It is broken, boiling is added to boil and extracts 2h, the mass ratio of Tongkat Ali and water is 1:10, the dregs of a decoction are filtered, the liquid spray being obtained by filtration is done
Tongkat Ali hot water extract's powder is obtained after dry.
Preferably, the preparation process of the Semen Cuscutae hot water extract is specially：Dry Semen Cuscutae is taken to crush, and adds water
It boils and extracts 3h, the mass ratio of Semen Cuscutae and water is 1:10, the dregs of a decoction are filtered, Tu are obtained after the liquid spray being obtained by filtration is dried
Sub- hot water extract's powder.
Preferably, the preparation process of the American Ginseng powder is specially：Dry American Ginseng is taken to crush, 80 mesh sieves is crossed, obtains
American Ginseng powder.
Further requirement protection aforementioned pharmaceutical compositions of the present invention are in the health products or drug for preparing treatment virile diesae
Purposes.
Due to the implementation of above technical scheme, the present invention has the following advantages that compared with prior art：The treatment of the present invention
The pharmaceutical composition of virile diesae can enhance immune function, rapid recovery fatigue, enhancing Male vitality, enhancement fecundity
With treatment male sexual disfunction, relevant healthcare product or drug can be prepared into.
Specific embodiment
Embodiment one：The preparation of pharmaceutical composition
The component of 1.1 pharmaceutical compositions
The dosage form of pharmaceutical composition in the present embodiment is capsule (hereinafter referred to as medicament capsule), and medicament capsule presses quality
Number meter, including following component：18.75 parts of agate card hot water extract, 18.75 parts of Tongkat Ali hot water extract, Semen Cuscutae heat
25 parts of water extract, 25 parts of Butea superba hot water extract, 12.5 parts of American Ginseng powder.
Specifically, every weight 0.4g of medicament capsule in the present embodiment, wherein the hot water extract of card containing agate 0.075g, east leather
Ali hot water extract 0.075g, Butea superba hot water extract 0.1g, Semen Cuscutae hot water extract 0.1g, American Ginseng powder
0.05g。
The preparation method of each component in 1.2 pharmaceutical compositions
In the present embodiment described briefly below in medicament capsule each component preparation process：
The preparation process of agate card hot water extract is：
The maca powder that 10kg is dried is broken, and adds 100kg boilings boiling extraction 2h, filters the dregs of a decoction, the liquid that will be obtained by filtration
1kg agate card hot water extract's powder is obtained after spray drying.
The preparation process of Butea superba hot water extract is：
The Butea superba that 25kg is dried crushes, and adds 250kg boilings boiling extraction 1h, filters the dregs of a decoction, the liquid that will be obtained by filtration
1kg Butea superba hot water extract's powder is obtained after spray body drying.
The preparation process of Tongkat Ali hot water extract is：
The Tongkat Ali tree root that 30kg is dried is taken to crush, adds 300kg boilings boiling extraction 2h, filters the dregs of a decoction, will be obtained by filtration
Liquid spray drying after 1kg Tongkat Ali hot water extract's powder.
The preparation process of Semen Cuscutae hot water extract is：
Dry 10kg Semen Cuscutaes is taken to crush, and add 100kg boilings boiling extraction 3h, filter the dregs of a decoction, the liquid that will be obtained by filtration
1kg Semen Cuscutae hot water extract's powder is obtained after spray body drying.
The preparation process of American Ginseng powder is：
The clean American Ginseng that 10kg is dried is taken to crush, 80 mesh sieves is crossed, obtains 9.8kg American Ginseng powders.
The preparation of 1.3 medicament capsules
By agate card hot water extract powder obtained above, Butea superba hot water extract powder, the extraction of Tongkat Ali hot water
Object powder, Semen Cuscutae hot water extract powder and American Ginseng powder are added and are uniformly mixed in proportion, are gone out with autoclave
After bacterium, capsule is packed into.
Embodiment two：Experimentation (materials and methods)
2.1 animal：Male SD rat 60, cleaning grade, weight (280 ± 20) g in August age, are tested by Kunming Medical University
Animal center provides.
2.2 experimental drug
1. medicament capsule：Specification：0.4g/；Face the suspension that the used time is made into the 0.4g/mL containing patent medicine with physiological saline,
Middle medicament capsule low dose group concentration is 0.4g/mL containing patent medicine (normal dose), middle dose group concentration is 0.8g/mL containing patent medicine
(2 times of normal dose), high dose group concentration are 0.12g/mL containing patent medicine (3 times of normal dose)；
2. Longbishu Jiaonang.：Specification：0.3g/, Kedi Pharmaceutical Co., Ltd., Shijiazhuang's production, lot number 010601；Face use
The suspension of Shi Peicheng 0.03g/mL containing patent medicine；
3. testosterone propionate parenteral solution：Specification 25mg/1mL, is produced by Tianjin KingYork Amino Acid Co., Ltd.；
Testosterone 4. (T) assay kit：Beijing North Institute of Biological Technology；Estradiol (E2) assay kit：Beijing
Northern biotechnology research institute；Epidermal growth factor (EGF) kit：Senxiong Science ＆ Technology Industry Co., Ltd., Shanghai.
It is prepared by 2.3 hyperplasia of prostate animal models：(with reference to the Ministry of Public Health《New drug (Western medicine) preclinical study guideline is converged
It compiles》Modeling)
Male SD rat is commonly raised to 1 week to adapt to environment, and through commonly observe it is without exception after, noted with ketalar
It penetrates liquid 100mg/kg and intraperitoneal anesthesia is carried out to male SD rat, after anaesthetizing successfully, rat is fixed on operating table, skin is conventional
It sterilizes, extracts bilateral testes through scrotum under aseptic condition, ligation stump is to ensure to stop blooding, skin suture.After observing 1 week, every
Testosterone propionate 3.5mg/kg is subcutaneously injected by weight in rat, and 1 time/d, successive administration 30 days causes hyperplasia of prostate animal mould
Type.
2.4 groupings and administration：
Grouping：It takes 10 to be only used as blank control group at random 60 rats, does sham-operation；Remaining rat makes hyperplasia of prostate
Model.50 rats of conventional modeling are randomly divided into 5 groups, every group of l0 is only, specific as follows：A, model group；B, Longbishu Jiaonang.
Control group；C, medicament capsule low dose group；D, medicament capsule middle dose group；E, medicament capsule high dose group.
Medication：A groups give physiological saline gavage by 1mL/100g weight, and B groups give the retention of urine by lmL/100g weight
Relax suspension oral gavage, and C, D, E group give basic, normal, high acute drug capsule suspension oral gavage respectively by 1mL/100g weight, daily
1 time, continuous 30 days.It after 30 days, puts to death together, takes prostata tissue to be measured.
2.5 Testing index：
Prostate wet weight and prostate index：In 2h after the last administration (being deprived of food but not water 12h), rat is weighed respectively, fast
Speed takes prostate to claim its prostate wet weight, calculates prostate index (prostate index=prostate wet weight g/ mouse weight g).
Detect T, E2, EGF：Prostate is divided into two parts by level, is claimed prostate lobus lateralis sinister 300mg, is added people's 1mL ice physiology
Brine, 4 DEG C homogenate, with 3000rpm centrifuge 15min, take prostata tissue homogenate supernatant measure prostata tissue in E2, T,
EGF is horizontal.
Measure the gland density and Histomorphological of prostate：Right side prostata tissue is taken to be fixed on 10% formal
In woods solution, paraffin embedding, section, HE dyeing, the variation of light Microscopic observation each group prostatic histomorphology.
Measure the gland density of prostate：Using General stereoscopic meterological assay method, using test lattice point analytic approach, meter
The intersection points on body of gland and the percentage for intersecting points in reference system are calculated, is the gland density of prostate, each internal organs are surveyed
It is 3 times fixed.
2.6 statistical method
Database established using 17.0 statistical packages of SPSS to experimental data, and withRepresent each quantitative target
Average value and degree of scatter.The comparison of the multiple sample averages of Group Design is examined using ANOVA (variance analysis), multiple samples
Each two mean compares between mean is examined using t.
Embodiment three：Results and discussion
The influence of 3.1 pairs of prostatic hyperplasia model rat prostate weights, prostate index and gland density
Medicament capsule in embodiment one using the method in embodiment two is tested, and detects medicament capsule to preceding
The influence of row gland model of hyperplasia rat prostate weight, prostate index and gland density, experimental result are shown in Table 1.
1 medicament capsule of table to benign prostatic hyperplasia in rats model prostate wet weight, prostate index and gland density influence (N=10)
Note：Compared with blank group,**P<0.01；Compared with model group,△△P<0.01
There is table 1 to understand, compared with blank group, model group rats prostate wet weight, prostate index and gland density are all aobvious
Writing increases (P<0.01) the apparent hyperplasia of model group rats prostate, model copy success, are illustrated.Compared with model group, high, middle dose
Amount medicament capsule group and the retention of urine group of relaxing can significantly reduce prostatic hyperplasia model rat prostate weight in wet base, prostate index and preceding
Volume density (the P of row gland body of gland<0.01), medicament capsule low dose group can significantly reduce rat prostate weight in wet base (P<0.01), may be used
It is substantially reduced prostate index (P<0.05).
The influence of T, E2 and EGF in 3.2 pairs of hyperplasia of prostate rat model prostata tissues
Medicament capsule in embodiment one is tested using the method in embodiment two, detection medicament capsule is to forefront
The influence of T, E2 and EGF, experimental result are shown in Table 2 in gland hyperplasia rat model prostata tissue.
2 medicament capsule of table to benign prostatic hyperplasia in rats model prostate be homogenized in T, E2, EGF level influence (n
=10)
Note：Compared with blank group,**P<0.01；Compared with model group,△△P<0.01
Table 2 shows with blank group ratio, the horizontal significantly rise (P of T, EGF in the homogenate of model group rats prostate<0.01).
With model group ratio, high, medium and low dose drug Capsules group and the retention of urine relax group can significantly reduce T in the homogenate of rat model prostate,
EGF levels (P<0.01) the influence unobvious of E2 levels during each group is homogenized prostata tissue, are tested.
The observation of 3.3 each group prostatic histomorphologies
See that body of gland arrangement is close under blank group mirror, visible apparent interstitial between body of gland, lumen of gland is without expansion, galandular epithelium individual layer column
Shape；The apparent hyperplasia of body of gland is seen under model group mirror, lumen of gland is expanded in cryptomere, and not of uniform size, most galandular epithelium papillary hyperplasias are apparent
It dashes forward to intracavitary, interstitial edema, hemostasis；The retention of urine, which relaxes, sees that prostate gland hyperplasia degree has certain improvement compared with model group under group mirror；Medicine
Composite capsule is high, sees that prostate gland has certain hyperplasia under middle dose group dosage group mirror, and a small number of lumens of gland are expanded in cryptomere, on local gland
Skin is prominent to intracavitary in mamillary, is greatly improved compared with model group；See prostate gland under the sensible capsule low dose group mirror in forefront
Hyperplasia has certain improvement compared with model group.
Example IV：Informal clinical test
4.1 hypertrophy of the prostate
100 50-85 Sui male prostate hypertrophy patients, take the medicament capsule prepared in embodiment one 3 months, and every 4
It is once.Effective reaction rate is 80%, and related symptoms can once be alleviated by taking, and effect is as follows：
3 medicament capsule of table treats the effect of hypertrophy of the prostate patient
4.2 improve male's sexual
200 40-60 Sui males, take the medicament capsule prepared in embodiment one 3 months, and every 5 days once.Each taking
After 20h, male's sexual desire significantly improves；Male suddenly increases in morning within 5 days；Life quality greatly improves.Effective reaction rate is
More than 95%, Details as Follows：
4 medicament capsule of table improves the effect of male's sexual
| Symptom | Before taking | After taking (after 20h) |
| Penile erectile dysfunction syndrome | It erects difficult | It is easy to erect |
| Premature ejaculation | Premature ejaculation | The sexual life time was up to 15 minutes or more |
4.3 treatment male sterilities
10 40-50 Sui males had childbearing history at more than 20 years old, and the atoke after 32 years old, atoke state continues
Up to 10 years or more.Preparental plan is proceeded by within 40 years old or so, prepares 2 years or more infertile persons, takes the medicine prepared in embodiment one
The composite capsule 1-2 months, successful pregnancies.Reactivity is 100%.
The pharmaceutical composition of the present invention can significantly reduce prostate wet weight in prostatic hyperplasia model rat, prostate
The volume density of index and prostate gland and to significantly reduce T, EGF in the homogenate of rat model prostate horizontal；And through it is non-just
Formula clinical research finds that the medicine composite for curing hyperplasia of prostate in the present invention has good effect.
The pharmaceutical composition of the present invention can enhance immune function, rapid recovery fatigue, enhancing Male vitality, enhancement reproduction
Ability function and treatment male sexual disfunction, can be prepared into relevant healthcare product or drug.
The above embodiments merely illustrate the technical concept and features of the present invention, and its object is to allow person skilled in the art
Scholar can understand present disclosure and implement according to this, and it is not intended to limit the scope of the present invention, it is all according to the present invention
The equivalent change or modification that Spirit Essence is made, should be covered by the protection scope of the present invention.
Claims (10)
1. a kind of pharmaceutical composition for treating virile diesae, which is characterized in that described pharmaceutical composition according to the mass fraction, including
Following component：10-30 parts of agate card hot water extract, 10-30 parts of Tongkat Ali hot water extract, Semen Cuscutae hot water extract 15-
40 parts, 15-40 parts of Butea superba hot water extract, 5-20 parts of American Ginseng powder.
2. the pharmaceutical composition for the treatment of virile diesae according to claim 1, which is characterized in that described pharmaceutical composition is pressed
Mass fraction meter, including following component：18.75 parts of agate card hot water extract, 18.75 parts, Tu of Tongkat Ali hot water extract
Sub- 25 parts of hot water extract, 25 parts of Butea superba hot water extract, 12.5 parts of American Ginseng powder.
3. the pharmaceutical composition for the treatment of virile diesae according to claim 1, which is characterized in that described pharmaceutical composition
Dosage form is effervescent tablet, buccal tablet, granule, capsule or oral liquid.
4. a kind of preparation method for the pharmaceutical composition for treating virile diesae, which is characterized in that described pharmaceutical composition presses quality
Number meter, including following component：10-30 parts of agate card hot water extract, 10-30 parts of Tongkat Ali hot water extract, Semen Cuscutae heat
15-40 parts of water extract, 15-40 parts of Butea superba hot water extract, 5-20 parts of American Ginseng powder；
The preparation method of described pharmaceutical composition includes following preparation process：
The preparation process of the agate card hot water extract is：Dry maca powder is broken, and add boiling boiling extraction, the dregs of a decoction are filtered,
Get Ma Ka hot water extract's powder after the liquid spray being obtained by filtration is dried；
The preparation process of the Butea superba hot water extract is：Dry Butea superba is crushed, and adds boiling boiling extraction, filters medicine
Slag obtains Butea superba hot water extract's powder after the liquid spray being obtained by filtration is dried；
The preparation process of the Tongkat Ali hot water extract is：Dry Tongkat Ali is crushed, adds boiling boiling extraction, filtering
The dregs of a decoction obtain Tongkat Ali hot water extract's powder after the liquid spray being obtained by filtration is dried；
The preparation process of the Semen Cuscutae hot water extract is：Dry Semen Cuscutae is crushed, and adds boiling boiling extraction, filters medicine
Slag obtains Semen Cuscutae hot water extract's powder after the liquid spray being obtained by filtration is dried；
The preparation process of the American Ginseng powder is：Dry American Ginseng is taken to crush, sieves, obtains American Ginseng powder.
5. the preparation method of the pharmaceutical composition for the treatment of virile diesae according to claim 4, which is characterized in that the agate
Card hot water extract preparation process be specially：Dry maca powder is broken, and add the quality of boiling boiling extraction 2h, Ma Ka and water
Than for 1:10, the dregs of a decoction are filtered, get Ma Ka hot water extract's powder after the liquid spray being obtained by filtration is dried.
6. the preparation method of the pharmaceutical composition for the treatment of virile diesae according to claim 4, which is characterized in that described gorgeous
The preparation process of palas hot water extract is specially：Dry Butea superba is crushed, and adds boiling boiling extraction 1h, Butea superba and water
Mass ratio be 1:10, the dregs of a decoction are filtered, Butea superba hot water extract's powder is obtained after the liquid spray being obtained by filtration is dried.
7. the preparation method of the pharmaceutical composition for the treatment of virile diesae according to claim 4, which is characterized in that the east
Leather Ali hot water extract preparation process be specially：Dry Tongkat Ali tree root is taken to crush, adds boiling boiling extraction 2h, east leather
The mass ratio of Ali and water is 1:10, the dregs of a decoction are filtered, the extraction of Tongkat Ali hot water is obtained after the liquid spray being obtained by filtration is dried
Object powder.
8. the preparation method of the pharmaceutical composition for the treatment of virile diesae according to claim 4, which is characterized in that the Tu
The preparation process of the sub- hot water extract of silk is specially：Dry Semen Cuscutae is taken to crush, and adds boiling boiling extraction 3h, Semen Cuscutae and water
Mass ratio be 1:10, the dregs of a decoction are filtered, Semen Cuscutae hot water extract's powder is obtained after the liquid spray being obtained by filtration is dried.
9. the preparation method of the pharmaceutical composition for the treatment of virile diesae according to claim 4, which is characterized in that the west
The preparation process of American ginseng powder is specially：Dry American Ginseng is taken to crush, 80 mesh sieves is crossed, obtains American Ginseng powder.
10. the pharmaceutical composition described in claim 1-3 any one is in the health products or drug for preparing treatment virile diesae
Purposes.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810118690.9A CN108096313A (en) | 2018-02-06 | 2018-02-06 | A kind of pharmaceutical composition for treating virile diesae and its preparation method and application |
| PCT/CN2019/073552 WO2019154161A1 (en) | 2018-02-06 | 2019-01-29 | Pharmaceutical composition for treating male diseases, and preparation method therefor and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810118690.9A CN108096313A (en) | 2018-02-06 | 2018-02-06 | A kind of pharmaceutical composition for treating virile diesae and its preparation method and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108096313A true CN108096313A (en) | 2018-06-01 |
Family
ID=62221907
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810118690.9A Pending CN108096313A (en) | 2018-02-06 | 2018-02-06 | A kind of pharmaceutical composition for treating virile diesae and its preparation method and application |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN108096313A (en) |
| WO (1) | WO2019154161A1 (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108904777A (en) * | 2018-08-14 | 2018-11-30 | 中商国能孵化器集团有限公司 | A kind of pharmaceutical composition and preparation method thereof for treating prostate and gynaecological disease |
| CN109692263A (en) * | 2019-01-15 | 2019-04-30 | 林嗣松 | A kind of herbal mixture and its application in column gland hyperplasia before the treatment |
| WO2019154161A1 (en) * | 2018-02-06 | 2019-08-15 | 海文健康科技（深圳）有限公司 | Pharmaceutical composition for treating male diseases, and preparation method therefor and use thereof |
| CN114052256A (en) * | 2021-12-10 | 2022-02-18 | 北京玛尼布生物科技有限公司 | Ginseng and maca solid product |
| CN115105569A (en) * | 2021-03-23 | 2022-09-27 | 韩蕊 | A Chinese medicinal composition for relieving fatigue and improving sexual function of male, and its preparation method |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016148545A1 (en) * | 2015-03-18 | 2016-09-22 | 주식회사 파미니티 | Composition for preventing or improving male menopause symptoms |
| CN106616948A (en) * | 2017-02-06 | 2017-05-10 | 福建万亿店中店电子商务有限责任公司 | Cordyceps adenosine-containing healthcare capsule capable of enhancing sexual function |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3502374B2 (en) * | 1999-08-27 | 2004-03-02 | チェイル ジェダン コーポレーション | Extracts derived from Pueraria mirifica, Butea Superba and / or Mukna Koretch and methods for extracting the same |
| CN106109528A (en) * | 2016-07-14 | 2016-11-16 | 上海新肌生物科技有限公司 | Nanoscale Eurycoma longifolia and Maca extraction process |
| CN106174573A (en) * | 2016-07-29 | 2016-12-07 | 黄毅 | Eurycoma longifolia and Maca extraction process |
| CN107137443A (en) * | 2017-04-26 | 2017-09-08 | 丽江久康生物科技有限公司 | A kind of composition for relieving fatigue, preparation method and applications |
| CN108096313A (en) * | 2018-02-06 | 2018-06-01 | 张南 | A kind of pharmaceutical composition for treating virile diesae and its preparation method and application |
-
2018
- 2018-02-06 CN CN201810118690.9A patent/CN108096313A/en active Pending
-
2019
- 2019-01-29 WO PCT/CN2019/073552 patent/WO2019154161A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016148545A1 (en) * | 2015-03-18 | 2016-09-22 | 주식회사 파미니티 | Composition for preventing or improving male menopause symptoms |
| CN106616948A (en) * | 2017-02-06 | 2017-05-10 | 福建万亿店中店电子商务有限责任公司 | Cordyceps adenosine-containing healthcare capsule capable of enhancing sexual function |
Non-Patent Citations (3)
| Title |
|---|
| 董广民: "《家庭医学健康百科全书》", 31 May 2015, 中医古籍出版社 * |
| 谭元生 等: "《新编中医手册》", 31 July 2017, 湖南科学技术出版社 * |
| 邹莹 等: "玛咖水提物抗小鼠前列腺增生作用", 《食品与生物技术学报》 * |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019154161A1 (en) * | 2018-02-06 | 2019-08-15 | 海文健康科技（深圳）有限公司 | Pharmaceutical composition for treating male diseases, and preparation method therefor and use thereof |
| CN108904777A (en) * | 2018-08-14 | 2018-11-30 | 中商国能孵化器集团有限公司 | A kind of pharmaceutical composition and preparation method thereof for treating prostate and gynaecological disease |
| CN109692263A (en) * | 2019-01-15 | 2019-04-30 | 林嗣松 | A kind of herbal mixture and its application in column gland hyperplasia before the treatment |
| CN109692263B (en) * | 2019-01-15 | 2021-06-25 | 林嗣松 | Compound traditional Chinese medicine and application thereof in treating prostatic hyperplasia |
| CN115105569A (en) * | 2021-03-23 | 2022-09-27 | 韩蕊 | A Chinese medicinal composition for relieving fatigue and improving sexual function of male, and its preparation method |
| CN114052256A (en) * | 2021-12-10 | 2022-02-18 | 北京玛尼布生物科技有限公司 | Ginseng and maca solid product |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2019154161A1 (en) | 2019-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108096313A (en) | A kind of pharmaceutical composition for treating virile diesae and its preparation method and application | |
| CN105106852A (en) | Traditional Chinese medicine preparation for treating hyperplasia of mammary glands and breast cancer | |
| CN102225181A (en) | Medicament for treating benign prostatic hyperplasia disease and preparation method thereof | |
| CN104491661B (en) | A kind of Chinese medicine composition for being used to treat prostatitis or hyperplasia of prostate | |
| CN102488740A (en) | Application of chickpea sprout extracts in medicines for preventing deficiency of estrogen | |
| CN103157062B (en) | Medicine composition curing gynaecological mass diseases such as fibroids and preparation method and application thereof | |
| CN103041305B (en) | Traditional Chinese medicine composition for curing hyperplasia of mammary glands and preparation method thereof | |
| CN102793878B (en) | A kind of gout fast analgesic paste | |
| CN109125458A (en) | Application of the Folium Citri tangerinae extract in preparation treatment/prevention autoimmune orchitis drug | |
| CN1833687A (en) | Chinese medicinal compsns. for treating digestive ulcer and chronic gastritis, its prepn. and usage | |
| CN105770691A (en) | Medicinal preparation for treating cervical cancer and application thereof | |
| CN105232605A (en) | Traditional Chinese medicine compound treating prostatic hyperplasia and preparation and application thereof | |
| CN105194676B (en) | It is a kind of to treat pharmaceutical composition of hyperlipidemia and preparation method thereof | |
| CN109248269A (en) | A kind of traditional Chinese medicine for outer use for treating hyperplasia of mammary glands | |
| CN104367946A (en) | Traditional Chinese medicine suppository for treating chronic endometritis and preparation method thereof | |
| CN102526238A (en) | Chinese medicinal composition for preventing and treating rheumatoid arthritis | |
| CN114558090B (en) | Medicine for treating benign prostatic hyperplasia | |
| CN107213426A (en) | Treat Chinese patent drug of mammary gland disease and preparation method thereof | |
| CN105998290A (en) | Traditional Chinese medicine composition for treating early woman amenorrhea and preparing method thereof | |
| CN102670858B (en) | Lotion for treating inflammatory external hemorrhoids | |
| CN107661474A (en) | Treat Chinese medicine preparation of chronic pelvic inflammatory disease and preparation method thereof | |
| CN101244174B (en) | Medicine for treating angiitis and preparation thereof | |
| CN104971308A (en) | Traditional Chinese medicine composition for treating chronic prostatitis | |
| CN104857061A (en) | Traditional Chinese medicine composition for treating uterine tumor | |
| CN103989761B (en) | One treats mastopathy Chinese medicine preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20190225 Address after: 518000 Room 301, 3rd Floor, Block E, Sanxianghai, 2277 Keyuan Avenue, Shekou Street, Nanshan District, Shenzhen City, Guangdong Province Applicant after: Haiwen Health Technology (Shenzhen) Co., Ltd. Address before: 210008 No. 33, Jinxianghe Road, Xuanwu District, Nanjing City, Jiangsu Province, 3 602 blocks Applicant before: Zhang Nan Applicant before: Zhong Rong |
|
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180601 |